- Trial phase
- Approved
- Time to market
- Already approved and marketed since 1997.
- Why 3/10
- BeneFIX is an already-approved, marketed drug with no pending regulatory decision, pivotal readout, or other hard binary catalyst scheduled in the next 12 months. It is a very small part of Pfizer's diversified $63B+ revenue portfolio, so even a material change in its sales would not drive a meaningful share-price move.
BeneFIX is a mature, approved product with no upcoming binary catalysts. The key thing to watch is whether biosimilar competition or gene therapy uptake (CSL's Hemgenix) erodes its market share over time, but this is a slow-moving, non-binary dynamic for a drug that is a tiny fraction of Pfizer's $63B+ revenue base.
Price Chart
Executive Summary
BeneFIX (nonacog alfa) is a recombinant coagulation factor IX replacement therapy approved by the FDA in 1997 for hemophilia B. Marketed by Pfizer, it is used for on-demand treatment, perioperative management, and routine prophylaxis of bleeding episodes. The drug competes in a crowded hemophilia B market against extended half-life products (Alprolix, Idelvion, Rebinyn), other standard half-life products (Ixinity, Rixubis), and emerging gene therapies (Hemgenix). BeneFIX is a mature, approved product with no upcoming binary catalysts, and it represents a very small fraction of Pfizer's $63B+ annual revenue, making it essentially immaterial to the stock's performance.
How It Works
BeneFIX is a recombinant (lab-made) version of human clotting factor IX, a protein that people with hemophilia B are missing or have too little of. When injected into a vein, it temporarily replaces the missing factor, allowing the blood to clot normally to stop or prevent bleeding episodes.
Trial Status
BeneFIX was FDA-approved on February 11, 1997. Pfizer has conducted post-approval studies including a Phase 3 trial of once-weekly prophylactic dosing (100 IU/kg), which met its primary endpoint with a statistically significant reduction in annualized bleeding rate versus on-demand treatment. Results were published in Haemophilia.
The Two-Sided Case
Upcoming Catalysts
- No upcoming binary catalysts identified. BeneFIX is a mature approved product with no pending FDA decisions, pivotal readouts, or regulatory actions scheduled.
Source Filing
The SecBot filing or press-release report that triggered this drug report:
PFIZER INC 8-K PFE ·Originating report